Haleon Cuts Full-Year Organic Revenue Growth Guidance

Haleon cut its full-year organic revenue growth guidance to approximately 2.5%, down from the 3%–5% range given in July. The company cited weaker cough, cold and flu product performance, particularly lower order volumes in North America. Organic revenue in respiratory health declined 2%, while oral health grew 8.8%. The article did not report a stock-price impact.